3 Cement and Building Products Maker, Air Compressors Maker and Fermentation Based Biopharma Company Stocks With a Strong Future Roadmap: JK Cement, Elgi Equipments and Concord Biotech
- November 6, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
JK Cement, Elgi Equipments and Concord Biotech: ROE of 12.9% to 19.3% and FY22 to FY26 revenue CAGR of 10.7% to 14.4%. Prices as of 5 Nov 2026.
Quick Answer
The three cement, air compressor and biopharma stocks to watch are JK Cement, Elgi Equipments and Concord Biotech. Their return on equity ranges from 12.9% to 19.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 14.4%. Elgi Equipments has the highest return on equity at 19.3%, while JK Cement has the fastest revenue growth at 14.4% a year. Prices are based on the 5 November 2026 close, and this article is educational, not investment advice.
Cement, air compressor and biopharma stocks bring together companies with a visible plan for the years ahead. JK Cement, Elgi Equipments and Concord Biotech cover a cement and building products maker, an air compressors maker and a biopharma company.
This list covers three cement, air compressor and biopharma stocks with complete current figures: JK Cement, Elgi Equipments and Concord Biotech. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Cement, Air Compressor and Biopharma Stocks?
Cement, air compressor and biopharma stocks are listed companies that produce cement and wall putty, manufacture air compressors for industry, and make fermentation-based active ingredients for global drug makers. Their earnings depend on construction demand, factory investment and drug supply contracts.
Cement, Air Compressor and Biopharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| JK Cement | 5,250.1 | 37,671 | 40.1 | 29.1 | 14.1 | 0.88 |
| Elgi Equipments | 547.1 | 17,259 | 38.5 | 44.4 | 19.3 | 0.24 |
| Concord Biotech | 672.7 | 13,421 | 49.2 | 36.0 | 12.9 | 0.00 |
On valuation, Elgi Equipments trades at a P/E below the industry P/E, while JK Cement and Concord Biotech trade above it, which reflects the growth the market already expects. Readers comparing cement, air compressor and biopharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cement, air compressor and biopharma stocks can use the coming numbers to test whether growth is holding.
Why Do Cement, Air Compressor and Biopharma Stocks Have a Strong Roadmap in India?
Cement, air compressor and biopharma stocks have a strong roadmap in India because growing construction work, steady factory investment and rising pharma outsourcing keep widening the market for these companies.
- Cement. Housing and roads need steady supply.
- Air compressors. Factories need dependable compressed air.
- Biopharma ingredients. Global drug makers need dependable inputs.
Why JK Cement Features Among These Cement, Air Compressor and Biopharma Stocks
Among the cement, air compressor and biopharma stocks on this list, JK Cement is a cement and building products company with plants in northern, western and southern India. It sells grey cement, white cement and wall putty, and it has a strong presence in the premium white cement segment.
Revenue rose from Rs 8,134 crore in FY22 to Rs 13,917 crore in FY26, a compound annual growth rate of 14.4%. Net profit grew from Rs 679 crore in FY22 to Rs 988 crore in FY26, which works out to a compound annual growth rate of 9.8%.
In the June 2026 quarter, revenue grew 19.4% year on year to Rs 4,071 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 37,671 crore. The stock trades at a P/E of 40.1, above the industry P/E of 29.1.
Roadmap: The company is expanding grey cement capacity in several regions and growing its white cement and putty range, which carries a strong brand. Housing and infrastructure activity supports steady cement demand.
What to watch: Track capacity additions, volume growth and realisation per tonne.
Why Elgi Equipments Features Among These Cement, Air Compressor and Biopharma Stocks
Among the building, machinery and drug shares on this list, Elgi Equipments, based in Coimbatore, is a major manufacturer of air compressors for industrial customers, selling in India and in international markets through its own subsidiaries.
In the June 2026 quarter, revenue grew 22.1% year on year to Rs 1,083 crore, while net profit rose 20.7% to Rs 103 crore. Revenue rose from Rs 2,580 crore in FY22 to Rs 4,068 crore in FY26, a compound annual growth rate of 12.1%.
Net profit grew from Rs 178 crore in FY22 to Rs 430 crore in FY26, which works out to a compound annual growth rate of 24.6%. The company has a return on equity of 19.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 17,259 crore. The stock trades at a P/E of 38.5, below the industry P/E of 44.4.
Roadmap: The company is growing its oil-free and energy-efficient compressor range and building a service-led annuity through spares and aftermarket support. International units add geographic spread, and automation in manufacturing improves efficiency.
What to watch: Follow industrial capital spending trends and the contribution of international subsidiaries.
Why Concord Biotech Features Among These Cement, Air Compressor and Biopharma Stocks
Among the three companies on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.
The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.
Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore.
Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What to watch: Monitor the pace of new product introductions and the contribution from formulations.
JK Cement vs Elgi Equipments vs Concord Biotech on Key Financials
The table below sets the three cement, air compressor and biopharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| JK Cement | 8,134 | 13,917 | 14.4% | 988 | 7.1% |
| Elgi Equipments | 2,580 | 4,068 | 12.1% | 430 | 10.6% |
| Concord Biotech | 736 | 1,107 | 10.7% | 259 | 23.4% |
Elgi Equipments posts the highest return on equity in this group at 19.3%. JK Cement combines the largest FY26 revenue at Rs 13,917 crore with the fastest revenue growth, a 14.4% compound annual rate. A useful habit with cement, air compressor and biopharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| JK Cement | 3,409 | 4,071 | 19.4% |
| Elgi Equipments | 886 | 1,083 | 22.1% |
| Concord Biotech | 218 | 270 | 24.2% |
Key Risks to Check Before Investing in Cement, Air Compressor and Biopharma Stocks
Every theme carries risks that deserve a check before any decision. For these cement, air compressor and biopharma stocks, the main points are: Long-term building, machinery and drug shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Housing cycles. Real estate and building demand can vary with rates and sentiment.
- Input costs. Metal and material prices can move margins.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter cement, air compressor and biopharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Cement, Air Compressor and Biopharma Stocks
Cement, air compressor and biopharma stocks suit investors who prefer to study business strength before price moves. JK Cement, Elgi Equipments and Concord Biotech each have a clear plan to grow. Based on the 5 November 2026 close, JK Cement trades at Rs 5,250.1, Elgi Equipments at Rs 547.1 and Concord Biotech at Rs 672.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these cement, air compressor and biopharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track cement, air compressor and biopharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are cement, air compressor and biopharma stocks?
Ans. Cement, air compressor and biopharma stocks are listed companies that produce cement and wall putty, manufacture air compressors for industry, and make fermentation-based active ingredients for global drug makers. Their earnings depend on construction demand, factory investment and drug supply contracts. This list looks at three of them, JK Cement, Elgi Equipments and Concord Biotech, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.
Which cement, air compressor and biopharma stocks are covered in this list?
Ans. This list covers JK Cement, Elgi Equipments and Concord Biotech. Based on the 5 November 2026 close, JK Cement traded at Rs 5,250.1, Elgi Equipments at Rs 547.1 and Concord Biotech at Rs 672.7. Their return on equity ranges from 12.9% to 19.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 14.4%.
Why do cement, air compressor and biopharma stocks have a strong future roadmap in India?
Ans. Cement, air compressor and biopharma stocks have a strong roadmap in India because growing construction work, steady factory investment and rising pharma outsourcing keep widening the market for these companies. The main drivers are as follows. Cement. Housing and roads need steady supply. Air compressors. Factories need dependable compressed air. Biopharma ingredients. Global drug makers need dependable inputs. Together these factors give the companies on this list a visible path for growth over the coming years.
How has JK Cement performed financially?
Ans. Revenue rose from Rs 8,134 crore in FY22 to Rs 13,917 crore in FY26, a compound annual growth rate of 14.4%. Net profit grew from Rs 679 crore in FY22 to Rs 988 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 19.4% year on year to Rs 4,071 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 37,671 crore. The stock trades at a P/E of 40.1, above the industry P/E of 29.1. Looking ahead, the company is expanding grey cement capacity in several regions and growing its white cement and putty range, which carries a strong brand. Housing and infrastructure activity supports steady cement demand.
How has Elgi Equipments performed financially?
Ans. Revenue rose from Rs 2,580 crore in FY22 to Rs 4,068 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 178 crore in FY22 to Rs 430 crore in FY26, which works out to a compound annual growth rate of 24.6%. In the June 2026 quarter, revenue grew 22.1% year on year to Rs 1,083 crore, while net profit rose 20.7% to Rs 103 crore. The company has a return on equity of 19.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 17,259 crore. The stock trades at a P/E of 38.5, below the industry P/E of 44.4. Looking ahead, the company is growing its oil-free and energy-efficient compressor range and building a service-led annuity through spares and aftermarket support. International units add geographic spread, and automation in manufacturing improves efficiency.
How has Concord Biotech performed financially?
Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What risks should investors check before buying cement, air compressor and biopharma stocks?
Ans. Investors should check a few risks before buying cement, air compressor and biopharma stocks. Housing cycles. Real estate and building demand can vary with rates and sentiment. Input costs. Metal and material prices can move margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of cement, air compressor and biopharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.